Search results

ImmunityBio IBRX enters 2026 with a commercial story that is unusually concentrated. Anktiva is the company’s first marketed product, and it is already the clear topline driver.

What matters now is

Senseonics SENS recently announced the European launch of its groundbreaking Eversense 365 CGM system, the world’s first continuous glucose monitoring (CGM) system designed to last an entire year

iShares MSCI South Korea ETF EWY is probably on the radar for investors seeking momentum. The fund just hit a 52-week high and has moved up 183.68% from its 52-week low price of $55.33 per share.

Gorman-Rupp (GRC) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with

Newell Brands Inc. NWL is expected to register a year-over-year decline in the top and bottom lines when it reports first-quarter 2026 results on May 1, before the opening bell. The Zacks Consensus

Trane Technologies plc TT is set to report first-quarter 2026 earnings on April 30, before the opening bell.

The company’s earnings surprise history has been impressive. It surpassed the Zacks

Investment banker Goldman Sachs recently raised its price target for UnitedHealth Group Incorporated (UNH) shares from $400 to $435, citing the company’s increased full-year guidance, announced in

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Ovintiv (OVV), which belongs to the

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Miami International Holdings, Inc

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Magna (MGA), which belongs to the Zacks

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider ANI

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Archer Daniels

Cognex CGNX is scheduled to report its first-quarter 2026 earnings results on May 6.For the first quarter of 2026, CGNX expects revenues between $235 million and $255 million, suggesting

Maximus Inc. MMS is benefiting from its strong presence in government health and human services, consistent cash generation, and reliable contract-driven business model. While the stock may not

Five Below, Inc. FIVE is leveraging a dual-engine growth model, with both traffic and ticket expansion contributing to its strong sales momentum. In fiscal 2025, the company’s customer-focused

Investors might want to bet on FTAI Aviation (FTAI), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is

Investors might want to bet on Laird Superfood, Inc. (LSF), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is

Bridgewater (BWB) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of

Vertiv Holdings Co. (VRT) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting

ImmunityBio (IBRX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the